Unlike traditional ablation treatments that use heat generated by radiofrequency energy to destroy the abnormal tissue, physicians at The Ohio State University Medical Center’s Richard M. Ross Heart Hospital are using a minimally invasive, cryoballoon treatment to correct paroxysmal atrial fibrillation (PAF). This catheter system uses freezing energy, or cryoablation, to eliminate electrical triggers from the abnormal tissue in or near the pulmonary veins. A cooling material is delivered within the catheter to freeze and destroy the cells at the entrance to the pulmonary veins.
“The value of the new technology over existing ablation methods is that it enables physicians to safely and effectively isolate the pulmonary veins,” says Dr. John Hummel, director of clinical electrophysiology research at Ohio State’s Medical Center. “This approach allows patients’ hearts to be restored to an appropriate rhythm so they can resume normal, daily activities following treatment.”
Atrial fibrillation (AF) is a rapid and irregular heart rhythm that originates from the top chambers of the heart called the atria. The rapid rate in the atria causes the bottom chambers of the heart, the ventricles, to also beat rapidly and irregularly, predisposing the patient to heart failure and stroke. In a manner similar to other pumps, the heart pump does not work as efficiently as it should when it is beating rapidly and irregularly. This inefficiency often causes symptoms such as a skipped heart beat, fatigue, shortness of breath and lack of energy or, in some instances, no symptoms at all. AF affects nearly three million people in the U.S.
Half of all diagnosed AF patients fail drug therapy, and if left untreated patients have up to a five times higher risk of stroke and an increased chance of developing heart failure.
Public Affairs and Media Relations